Prescribing Information and adverse event reporting can be found at the bottom of the page.
Welcome to Almirall
Driven by science and committed to patients
This is the philosophy which inspires Almirall to keep addressing the unmet needs of people living with skin conditions.
Our goal is to have a 360º approach to patient care, considering both physical symptoms and those closely associated with wellbeing and mental health. Ultimately, contributing to us becoming a leader in dermatology.
Pushing for breakthroughs in dermatology – our therapeutic focus
The focus of our innovation is clear: to find solutions that help people with skin diseases. We invest in innovative biologics and cutting edge treatments to improve patients’ lives.
Realising the ambition
Please click below if you would like more information on our products.
Klisyri®
Indicated for the field treatment of nonhyperkeratotic, non-hypertrophic actinic keratosis (grade 1) of the face or scalp in adults.1
Wynzora®
The first and only CAL/BDP cream that treats mild to moderate psoriasis vulgaris on the body and scalp.2,3
Ilumetri®
Indicated for the treatment of adults with
moderate to severe plaque psoriasis who are candidates for systemic therapy.4
Ebglyss®
Indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg who are candidates for systemic therapy.5
References
1. KLISYRI® SmPC. Almirall. 2. WYNZORA® SmPC. Almirall. 3. Praestegard M, et al. Dermatol Ther (Heidelb). 2022;12(10):2217-31. 4. ILUMETRI® SmPC. Almirall. 5. Ebglyss SmPC. Almirall.
UK-ILU-2400006 July 2024
